American Lung Association to support Lung-MAP trial

Published on:

Chicago, IL (December 15, 2014) — The American Lung Association announced today that it has signed an agreement with the Foundation for the National Institutes of Health (FNIH) to help support the Lung-MAP project, a groundbreaking clinical trial in squamous cell lung cancer that brings together the National Cancer Institute, SWOG Cancer Research, the FNIH, Friends of Cancer Research, pharmaceutical companies and eight advocacy partners.


Lung-MAP represents an innovative approach to identification of biomarkers (an important tool in lung cancer treatment) and development of additional targeted therapies. The study is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer. This groundbreaking approach to clinical trials should improve access to promising drugs for patients and ease the significant recruitment challenges involved in traditional lung cancer biomarker trials. This unique trial infrastructure is capable of testing as many as five to seven additional drugs over the next five years.


“The American Lung Association’s support of this project has been made possible through our new LUNG FORCE initiative and our commitment to invest more resources towards lung cancer research,” said Harold P. Wimmer, National President and CEO of the American Lung Association.  “This is an important step in enhancing our research portfolio aimed at lung cancer, which is the leading cancer killer of both men and women in the U.S.”


In support of this project, the Lung Association will raise awareness of Lung-MAP among its constituents through its communications channels, including the LUNG FORCE website, to help recruit patients and educate patients on the importance of clinical trials.  The Lung Association will also lend its support to the creation of an investigator training video and a patient recruitment video and support meetings of Lung-MAP scientific and organizational leadership.

Related Content

FDA says CT scans sometimes damage implantable cardiac electronic devices
Bilingual people have more efficient brains, imaging study shows
Use of AI opportunistic screening in CT for cardiovascular disease
ChatGPT is overly worried about ED patients
Low doses of radiation still increase risk of leukemia, lymphoma and myeloma
ACR offers resources to achieve radiology AI best practices

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.